Author Archives: Bruno Quinney

Breast cancer research
#Breast cancer #Clinical trial #Obesity #Phesi

Breast cancer is world’s most studied disease, report finds 

Breast cancer is the most studied disease globally for a fifth year running, a new report reveals.  Phesi’s annual report into the world’s most studied diseases found that breast cancer was the most studied across all subtypes, from triple-negative to PIK3CA. Also in the top five were solid tumours, strokes,… Read More

#Cancer Research #News

Europe
#Arthritis #Biosimilars #Europe #NHS #Ulcerative colitis (UC)

Alvotech launches Simponi biosimilar in Europe 

Biotechnology company Alvotech has announced the European launch of its first-in-market biosimilar to Simponi (golimumab).  AVT05, known as Gobivaz, is a prefilled syringe and autoinjector used for the treatment of adults with rheumatoid arthritis, psoriatic arthritis and ulcerative colitis, as well as in children with ulcerative colitis. Gobivaz becomes the first marketed biosimilar to… Read More

#News

Demyelination of neuron
#FDA #Priority Review #SynaptixBio

Rare disease drug development scheme welcomed by biotech sector 

The renewal of the US priority review voucher (PRV) is vital for the biotech sector, SynaptixBio CEO Dan Williams has said.  The US Food and Drug Administration (FDA)’s PRV scheme, designed to incentivise rare disease drug development, was reauthorised by the US House of Representatives on December 1.  … Read More

#News #Regulatory

#AI #Cell and gene therapy #Charles River #Drug discovery #European Commission #European Union #FDA #Immune cells #Korea #Obesity #Personalised medicine #Rare disease #Regulatory

DDW Highlights: 23 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a research team found that a hidden molecular switch fuels obesity. Elsewhere, AI-generated… Read More

#Podcasts

#AI #Cell and gene therapy #Charles River #Drug discovery #European Commission #European Union #FDA #Immune cells #Korea #Obesity #Personalised medicine #Rare disease #Regulatory

This week in Drug Discovery (15 – 19 December) 

News round-up for 15 – 19 December by Bruno Quinney, Content Team at DDW.  This week in DDW, a research team found that a hidden molecular switch fuels obesity. Elsewhere, AI-generated antibodies have been tolerated by human immune cells.  The top stories:    Scientists discover hidden molecular switch that… Read More

#News

Chemify's Chemifarm
#AI #Chemify #Drug discovery #Tuberculosis

Chemify receives $1.6 million to advance TB drug discovery 

Scottish tech company Chemify has received $1.6 million from the Gates Foundation to continue the discovery of small molecules for tuberculosis (TB).  Building on a successful collaboration with Lgenia, the expanded project will leverage Chemify’s automated platform to design and synthesise new drug leads, aiming to address one of the world’s most… Read More

#Business & Investment #News

Innovation Centre, London
#Medical Research Council #National Institute for Health Research #UK

New £50 million MRC Centre to transform clinical trials 

A new £50 million ($67 million) Medical Research Council Centre is set to overhaul clinical trials for UK patients.  The Medical Research Council Centre of Research Excellence in Clinical Trial Innovation, in partnership with the National Institute for Health and Care Research, will receive up to £50 million ($67 million) over… Read More

#News

amino acids chain
#Assays #Biotech #Digital workflow #Protein #Webinar

Webinar: How to advance protein analysis

In this webinar, Bio-Techne unveils the next evolution of the Leo System, expanding the capabilities of Simple Western Technology for high-throughput protein analysis. The Leo System now supports integrated dual fluorescence channels—Near-Infrared (NIR) and Infrared (IR)—alongside chemiluminescence, enabling simultaneous detection of multiple targets within 96 samples in a single… Read More

#News

Cell and gene therapy concept
#Cell and gene therapy #Charles River #Drug discovery

Charles River to support companies developing therapeutics 

Charles River Laboratories has announced drug discovery companies will receive scientific and commercial expertise as part of the second cohort of its Cell and Gene Therapy Incubator Program (CIP).  The CIP cohort includes six companies, four of which are advanced therapy developers (CureAge Therapeutics, InterAct Therapeutics, Jaan Biotherapeutics and Kopra Bio) and two enabling technology… Read More

#News

Hepatitis B
#Clinical trial #Genetic medicines #Viral hepatitis

nChroma Bio set to trial chronic hepatitis B virus treatment 

Genetic medicines company nChroma Bio has received a Certificate for Clinical Trial in Hong Kong to start the Phase I/II trial of its treatment for chronic hepatitis B virus (HBV).  CRMA-1001 is an optimised next-generation epigenetic silencer, designed to durably silence HBV antigen expression by methylating both covalently closed circular… Read More

#News

#AI #Allergen immunotherapy #Allergy #Alzheimer's #Biotech #China #Clinical trial #DDW Highlights podcast #Eli Lilly #Obesity #Osteoarthritis #Spinogenix

DDW Highlights: 16 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, innovative treatments showed potential to treat neurodegenerative diseases, allergies and arthritis. Elsewhere,… Read More

#Podcasts

#AI #Drug discovery #Immune cells

AI-generated antibodies tolerated by human immune cells 

AI-generated antibodies have been tolerated by human immune cells, drug discovery company Latent Labs has announced.  The antibody designs, generated by Latent Labs’ AI platform, reportedly displayed drug-like properties, including low ex vivo immunogenicity.   Latent Labs hopes its platform, built on its Latent-X2 model, could significantly shorten… Read More

#News

Cell therapy platform
#Cell therapy #Cellular Origins #Financing

Cellular Origins complete $40 million financing round  

TTP company Cellular Origins has completed a $40 million Series A financing round to accelerate its development of scalable cell therapy manufacture.  The Series A financing was led by Johnson & Johnson, through its corporate venture capital organisation, Johnson & Johnson Innovation, with the syndicate comprising Highland Europe, BGF,… Read More

#Business & Investment #News

Microscope
#Biobanking #Biospecimen research #Drug discovery #eBook

eBook: Foundations of biospecimen success

Advances in biospecimen science are resolving long-standing challenges that have historically hindered research quality, reproducibility, and innovation across drug discovery, translational medicine, and biobanking. These gaps limit scientific progress because even the most sophisticated analytical tools depend on high-quality, well-characterised human biological specimens. This custom eBook from BioIVT explores the… Read More

#News

Blood in a Petri dish
#Clinical trial #CSL #Haemophilia

Results confirm safety and durability of haemophilia drug 

Results from a Phase III trial have confirmed the durability and safety of a one-time infusion to treat adults living with moderate to severe haemophilia B.  Etranacogene dezaparvovec, developed by global biopharma company CSL, was studied in a Phase III open-label, single-dose, single-arm trial, with 54 male participants… Read More

#News